Weekly Update: March 14, 2022
If you’re a trading guru you see that the S & P has now crossed a milestone mark in that the 50 day moving average fell below the 200 day moving average indicating a severe downward trend and normally a technical “BUY” indicator.
The problem is that no one knows what damage extremely high-energy prices are doing to our economy and what the Nut case Putin has up his sleeve.
He and his military leaders were dumb enough to attack a nuclear plant sop who knows what they are capable of either by design or stupidity.
I’ll sit on the sideline thank you and I’ll bet a lot of smart money is there as well.
Wellll Everyone has an opinion- see below
Barrons March 14-22
The S&P 500 Just Hit a ‘Death Cross.’ Why It’s Good News for the Stock Market.
The S&P 500 has performed so poorly this year that it is now trading at a scarily low level. That usually presents an attractive opportunity for longer-term investors.
The market benchmark, down more than 11% for the year, just hit a “death cross.” That is when the index’s 50-day moving average falls below the 200-day number.
It’s a signal that something is up in the market, if anyone needed more evidence. In normal times, when stocks are rising, the average of recent prices is higher than the figure for 200 days because the longer-term figure includes levels when stocks were lower.
Stock prices have fallen below their long-term trend as investors consider the current formidable risks to the economy. The Russia-Ukraine war has led to sanctions on Russia’s commodity exports that have reduced the amount of those goods on the global market, sending prices through the roof.
The 21st Century Investment Bank Capital Raises + Strategic Advisory
Donald Capital is a boutique Investment Bank that focuses on raising capital for emerging growth companies in the U.S. and around the globe.
Ideally, we like to work with Private and Public companies with a good management team, a compelling business plan, and the ability to gain market share.
For more information go to: www.DonaldCapital-NY.com
The Premier Operating System for Publicly Traded Companies
Track your investors’ buying and selling behaviors and use those insights to engage them across marketing channels.
Know who’s buying and selling and monitor trading in real time. Unlock your shareholders contact info and build full contact profiles on your shareholders, including emails, phone numbers, and social media accounts to engage them and target new investors through media campaigns.
To schedule a demo email me at firstname.lastname@example.org or call 727-459-7378
03-07-2021 CanB Corp (OTC CANB)
Greenridge Global Research update
Up To 100 CBD Lab Lounges To Be Launched
Up To 100 CBD Lab Lounges To Be Launched. Yesterday, the Company announced a ten-year deal with American Development Partners (“ADP”) to finance and develop up to 100 CBD Lounges, similar to CANB’s Lab2 format at its Miami facility. The Lab2 concept, which is nearing completion, features a bar/lounge consumption area with viewing windows to see products, like gummies and gelato, being made. The ADP-developed lounges are expected to be similar, having a bar/lounge space with viewing windows to see various end products being produced. The lounges will serve CANB as a relatively cheap way to establish regional production and distribution, enable it to build its brands on a national level, engage in a wider range of product R&D, and increase branded product sales in the lounges. ADP has budgeted $4 million for each lounge (committing $200 million with an option for another $200 million), and will receive a 10% development fee and a 20-year lease on each lounge from CANB. No additional details were released, other than the Company noting no equity was involved in the deal. ADP has a history of real estate development projects, with clients ranging from Wendy’s, Subway, Hampton Inn, Gold’s Gym, and AutoZone, among many other nationwide chains.
01-20-2022 Coeptis Therapeutics, Inc. OTC COEP
Coeptis Therapeutics Establishes Scientific Advisory Board to Advance Cell Therapy Product Development
Newly formed Scientific Advisory Board includes three members from the prestigious Karolinska Institutet (KI)
WEXFORD, Pa., Jan. 20, 2022 /PRNewswire/ — Coeptis Therapeutics, Inc. (OTC PINK: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announces the formation of its Scientific Advisory Board (SAB), which will contribute key guidance on the advancement of the Company’s product portfolio highlighted by CD38-GEAR-NK, a cell therapy technology, and CD38-Diagnostic, an in vitro diagnostic, which the company is co-developing with VyGen-Bio, Inc.
The Scientific Advisory Board is comprised initially of three renowned scientific researchers from the Karolinska Institutet, Stockholm, Sweden; Evren Alici, M.D., Ph.D.; Hans-Gustaf Ljunggren, M.D., Ph.D; and Arnika Kathleen Wagner, Ph.D.
2-14-22 Antibe Therapeutics Inc. OTC ATBF (TSXV:ATE)
Antibe Therapeutics Reports Q3 2022 Interim Financial and Operating Results
– Acute pain clinical program for otenaproxesul initiating this quarter
– Ended quarter with a $59 million cash position
TORONTO, February 14, 2022–(BUSINESS WIRE)–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, has filed its financial and operating results for the fiscal quarter ended December 31, 2021.
“We’re excited to have launched otenaproxesul’s clinical program for post-operative pain and remain on track to begin Phase II in the fall. We’re also encouraged by draft guidance published last week by both the FDA and CDC, highlighting the urgent need for new non-opioid pain medications,” commented Dan Legault, Antibe’s CEO. “With our strong balance sheet, we’ve been able to advance multiple programs in parallel, including our inflammatory bowel disease program which targets a major need in an attractive market. At a corporate level, our disciplined approach to spending provides us with more than two years of cash runway. As the year progresses, we look forward to unlocking value for our shareholders as we achieve milestones across our development programs.”
2-2-2022 SRAX (NASDAQ: SRAX)
Replays Available From the Influential Companies of the 2022 Sequire Metals and Mining Conference
LOS ANGELES, Feb. 02, 2022 (GLOBE NEWSWIRE) — via InvestorWire – SRAX, Inc. (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, hosted the 2022 Sequire Metals & Mining Conference, a preeminent virtual investor event, on January 27.
This elite event featured presentations from over 70 premier metals and mining stock market companies, as well as talks with industry experts.
1-18-2022 SRAX (NASDAQ: SRAX)
SRAX Announces Q4 Shares Repurchased and Dividend Payment
LOS ANGELES, Jan. 18, 2022 (GLOBE NEWSWIRE) — via InvestorWire — SRAX, Inc. (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has announced the quantity of shares repurchased in the fourth quarter of 2021, as well as the first payment being made for the previously issued dividend.
Throughout the three months preceding December 31st, 2021, the Company repurchased approximately $800K worth of stock made up of 155,000 thousand shares of common stock at an average price of $5.12 per share. This was part of the Company’s $10 million share buyback program announced on August 17, 2021.
1-10-2022 SRAX (NASDAQ: SRAX)
Dawson James issues Research Update
Raising Estimates and Price Target to $13.00
|SRAX announced full year and Q1 revenue guidance far above our and consensus estimates. We are raising our estimates and price target, from $11.50 to $13.00 to reflect continued strong growth in the Sequire platform.|
We are raising our estimates for 2022 and our price target after the company announced revenue guidance for Q1 and the year far ahead of our and consensus estimates. For 2022 we are now projecting revenue of $45.5 million, at the low-end of company guidance of $46 to $48 million and an increase from our prior estimate of $38.4 million.
We estimate there were 250 Sequire customers at year-end 2021 and have modeled 415 by the end of 2022, an increase of 165, an acceleration from the 125 added in 2021. Average revenue per subscriber, per month, in 2021 was over $11,000. We have assumed this declines slightly, to $10,750 per month in 2022.
Check out our latest commercial properties including an Amazing Private Island or Resort Development Property in Panama
Message me on Linkedin and check our latest commercial listings:
Please subscribe to our newsletter to get ongoing Real Estate and Alternative Investing updates:
|March 14, 2022 |
COMPANY QUOTES, LISTINGS RESEARCH AND NEWS
Coeptis Therapeutics, Inc.
Antibe Therapeutics, Inc (ATBPF) Profile 11/11/2018 News
Can B Corp (CANB) Profile News
Endurance Exploration Group, Ltd (EXPL) Profile 03-26/19 News
Social Reality, Inc. (SRAX) Profile News
ValuEngine Weekly Report
ETFs combining Wealth Preservation and Equity Participation Objectives
March 13, 2022 by Herb Blank
Two months ago, I noted that ValuEngine models were predicting a down market for 2022 and wrote a column on redeployment of core assets for investors with short-to-medium equity time horizons. The question for investors concerned with a downturn is what to do and if reallocation from assets committed to core equity is required, how much should be reallocated and where should these assets go? It turned out to be quite timely as the Year-to-Date (“YTD”) S&P 500 ETF SPY is down more than 7.8%. I recommended that concerned investors consider moving about 30% of their current core equity exposure to less volatile options. This should allow them to better weather a potential storm without bailing out altogether.
Read Complete Report
ValuEngine Capital Management LLC (VECM) is pleased to announce the addition of Jordan Kimmel to the team as the new Chief Equity Strategist and portfolio manager. VECM is a Registered Investment Advisor (RIA) that invests based on the proprietary, quantitative research produced by ValuEngine Inc. It is an important partnership between two companies: ValuEngine conducts research, and ValuEngine Capital Management LLC actively trades client funds using this research.
To subscribe to our bulletins and receive content whenever it is published, subscribe at our blog HERE
Black Swan Research Coverage and Subscription Service
Event Calendar Updates
SRAX to Host the 2022 Sequire Metals & Mining Virtual Conference on January 27th, 2022 a great success
LOS ANGELES, Jan. 13, 2022 (GLOBE NEWSWIRE) — via InvestorWire — SRAX, Inc. (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, announced it will host the first ever Sequire Metals & Mining Conference, a one-day investor event featuring prominent public mining companies and industry experts.
Rocky Mountain Microcap Conference VIII.
November 3, 2021 conference at TopGolf in Centennial Colorado was a great success with a higher than normal turnout.
Check it out and watch the presentations at:
LD Micro Main Event
October 12-14 Los Angeles.
This conference was a great success
All presenting company video calls will be available to view for 3 months. Visit the event website to see all the presentations: https://ldmicrojune2021.mysequire.com/
Check the website for updates:
Visit our homepage for up to the minute Financial News, Quotes and our Latest Black Swan Connection Newsletter
-SMM Distribution Update-
SMM Global Twitter Acct (Impressions last 30 days) 520
Direct Email * 220,000